IC51 + HAVRIX
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Japanese Encephalitis
Conditions
Japanese Encephalitis
Trial Timeline
Sep 1, 2005 → Aug 1, 2008
NCT ID
NCT00596271About IC51 + HAVRIX
IC51 + HAVRIX is a phase 3 stage product being developed by Valneva SE for Japanese Encephalitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00596271. Target conditions include Japanese Encephalitis.
What happened to similar drugs?
3 of 20 similar drugs in Japanese Encephalitis were approved
Approved (3) Terminated (0) Active (17)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00596271 | Phase 3 | Completed |
Competing Products
20 competing products in Japanese Encephalitis